{
    "nct_id": "NCT06389786",
    "official_title": "Safe Omission of Pelvic Lymph Node Dissection (SOuND) During Radical Prostatectomy: Diagnostic Accuracy of RhPSMA-7.3(18F) PET/CT, MpMRI and Patient Clinical Factors to Predict Lymph Node Metastasis",
    "inclusion_criteria": "* Male subjects with at least age 30 to 85\n* Primary diagnosis of prostate cancer selected for surgical intervention (radical prostatectomy with extended lymph node dissection)\n* Primary diagnosis of untreated American Urological Association (AUA) guidelines high-risk localized prostate cancer, hormone-na√Øve prostate cancer via contrast enhanced prostate MRI + tissue sampling\n* Planned elective radical prostatectomy with extended pelvic lymph node dissection\n* Clinical oligometastatic disease with < 3 nodes positive on 18F-rhPSMA-7.3 PSMA\n* Patient has the willingness to comply with instruction of the investigator\n* Patient has the willingness to comply with follow-up surveillance\n* Have ability to provide full written consent\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 30 Years\nMust have maximum age of 85 Years",
    "exclusion_criteria": "* High-risk cancer planned for neoadjuvant therapy\n* Patients with a history of more than two weeks treatment with immunosuppressants (including systemic corticosteroids), cytotoxic chemotherapy within one month prior to initial screening, or who receive such medications during the screening period, or who are anticipated to require such medications during the course of the study\n* Patients that have had prior hormonal therapy such as Lupron or oral antiandrogens\n* Clinical oligometastatic disease with > 3 nodes positive on 18F-rhPSMA-7.3 PSMA\n* Previous history of pelvic radiation\n* Patients with obesity defined as body mass index (BMI) > 40 kg/m^2\n* History of prior mesh for inguinal hernia repair\n* Scheduled at the time of screening to undergo chemotherapy, radiation, hormone therapy, or open surgery during the study period\n* Inability to lie still for 75 minutes during 18F-rhPSMA-7.3 PSMA PET-MRI imaging\n* Any neurologic disorder or psychiatric disorder that might confound postsurgical assessments\n* Has any condition(s), which seriously compromises the subject's ability to participate in this study, sign consent, or has a known history of poor adherence with medical treatment\n* Received administration of an investigational drug within 30 days prior to study, and/or has planned administration of another investigational product or procedure during participation in this study",
    "miscellaneous_criteria": ""
}